Janssen Search
Search results
Johnson & Johnson submits application to the European Medicines Agency for DARZALEX® (daratumumab)-based quadruplet therapy for the treatment of patients with transplant-eligible, newly diagnosed multiple myeloma
Mar 06, 2024 Belgium Submission supported by data from Phase 3 PERSEUS study, which showed the daratumumab subcutaneous formulation-based regimen significantly reduced the risk of progression or death, compared to standard of care regimen. [1] BEERSE, ...
Partnering with NYU to Evaluate CU Requests
Partnership to Help Patients Request Access to Investigational Medicines Decisions on compassionate use (CU) requests are some of the most difficult that any company can face. To enhance our long-standing commitment to ethical and patient-centered ...
Teri L. Lawver
TERI L. LAWVER WORLDWIDE VICE PRESIDENT IMMUNOLOGY Teri Lawver is Worldwide Vice President for the Immunology Therapeutic Area with Janssen Pharmaceutical Companies of Johnson & Johnson. Together with the Immunology Research & Development ...
Joseph Hedrick, Ph.D.
JOSEPH HEDRICK, PH.D. HEAD, TYPE 1 DIABETES VENTURE WORLD WITHOUT DISEASE ACCELERATOR As Head of the Type 1 Diabetes (T1D) Venture within the World Without Disease Accelerator (WWDA), Joe leads efforts utilizing the rapidly emerging science of immune ...
Jan Wehkamp, M.D.
JAN WEHKAMP, M.D. VICE PRESIDENT GASTROENTEROLOGY DISEASE AREA LEADER Jan Wehkamp, M.D. is Vice President, Gastroenterology Disease Area Leader for the Immunology Therapeutic Area at Janssen Research & Development, LLC. In this role, he is responsible ...
WCLC 2021
--> Welcome to the Janssen Oncology WCLC Virtual Newsroom At the Janssen Pharmaceutical Companies of Johnson & Johnson, our commitment to patients, caregivers and clinicians goes beyond medicine. Our goals are big. We aim to eliminate cancer. ...
Kevin Hamill
KEVIN HAMILL VICE PRESIDENT JANSSEN BUSINESS DEVELOPMENT IMMUNOLOGY Kevin Hamill is Vice President, Business Development for the Immunology Therapeutic Area (TA) at Johnson & Johnson Innovation, Janssen Business Development. In this role, he leads all ...
ASCO 2023
Welcome to the Janssen Oncology Virtual Newsroom Peter Lebowitz, M.D., Ph.D. Global Therapeutic Area Head Oncology Janssen Research & Development, LLC Tyrone Brewer U.S. President Oncology Janssen Biotech, Inc. Latest News Janssen Highlights ...
Celebrating a New Era in Bladder Cancer Treatment
Celebrating a New Era in Bladder Cancer Treatment As we seek to increase awareness of bladder cancer and the patients we serve, it is important to celebrate the enormous strides we have made in further understanding this disease. Recent scientific ...
Connecting Clinical Research to Communities for Better Health Outcomes
Connecting Clinical Research to Communities for Better Health Outcomes In this article, senior Janssen leaders discuss strategies for shaping more diverse, inclusive, and equitable clinical trials. How many ways might Janssen—and the industry at large ...